載入...
The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
The group 2 metabotropic glutamate receptor (mGluR2/3) agonist, pomaglumetad methionil (POM), showed promise as a novel antipsychotic in preclinical research but failed to show efficacy in clinical trials, though it has been suggested that it may be effective in certain patient populations. Although...
Na minha lista:
| 發表在: | Neuropsychopharmacology |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7547679/ https://ncbi.nlm.nih.gov/pubmed/32663839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41386-020-0764-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|